CIITA-modified glioblastomas vaccinate and induce cross-protection against heterologous wild-type glioblastomas

CIITA-modified glioblastomas vaccinate and induce cross-protection against heterologous wild-type glioblastomas

Abstract Background Glioblastoma (GBM) is a highly malignant brain tumor with poor outcome, despite current therapies. CIITA-modified tumor cells, capable of presenting antigens via MHC-II, show promise in eliciting effective antitumor immune responses. The efficacy of the CIITA-based vaccination st...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrea Gatta, Amruth K. B. Shaik, Mariam Shallak, Anna Maria Chiaravalli, Michele Cerati, Stefano La Rosa, Roberto S. Accolla, Greta Forlani
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Journal of Translational Medicine
Subjects:
Glioblastoma
CT-2A
Immunotherapy
Vaccine
Tumor associated antigens
Cross-protection
Online Access:https://doi.org/10.1186/s12967-025-06816-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12967-025-06816-5

Similar Items